Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.36 |
| ▸ | PRKCH | P24723 | 8/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 7/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.35 |
| ▸ | PKN1 | Q16512 | 3/20 | 0.35 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.35 |
| ▸ | PRKCA | P17252 | 2/20 | 0.35 |
| ▸ | PRKCB | P05771 | 2/20 | 0.35 |
| ▸ | LATS1 | O95835 | 1/20 | 0.35 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500780 | 0.70 | ALDH1A1 (0.41) | PLCG1ROCK2ROCK1 | |
| SCHEMBL6700969 | 0.69 | KDR (0.46) | — | |
| SCHEMBL28077694 | 0.68 | KDM4E (0.40) | PRKCDROCK2PRKCASCDCHEK1 | |
| SCHEMBL3810001 | 0.67 | PRKCH (0.43) | PRKCHPRKCQPRKCEPRKCDROCK2 | |
| SCHEMBL17008796 | 0.66 | HTT (0.38) | — | |
| SCHEMBL3808178 | 0.66 | POLB (0.45) | PRKCHPRKCQPRKCEPRKCDROCK2 | |
| SCHEMBL2296005 | 0.65 | ALDH1A1 (0.50) | PRKCHPRKCQPRKCEPRKCDROCK2 | |
| SCHEMBL28089055 | 0.65 | ALDH1A1 (0.42) | HRH3 | |
| SCHEMBL646539 | 0.65 | DPP4 (0.47) | — | |
| SCHEMBL6702643 | 0.65 | PRKCH (0.45) | PRKCHPRKCQPRKCEPRKCDROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | PLCG1 3878/4885PRKCH 3207/4885PRKCQ 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.